Form 4: Chemed Corp Director Ron DeLyons Acquires 277 Shares of Capital Stock

Director Ron DeLyons acquired 277 shares of Chemed Corp capital stock at a price of $579.04 on May 19, 2025.

Summary

• On May 19, 2025, Ron DeLyons, a director of Chemed Corp, acquired 277 shares of the company's capital stock.
• The acquisition price was $579.04 per share.
• Following the transaction, DeLyons directly owns 1,666 shares of Chemed Corp capital stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of a stock purchase by a director. While insider buying can be seen as a positive signal, the impact is likely limited.

Positives

• A director's purchase of company stock can be seen as a positive signal, indicating confidence in the company's future prospects.

Future Outlook

There is no future outlook provided in this document.

Industry Context

Form 4 filings are routine disclosures required by the SEC to ensure transparency in insider trading activities. They provide insights into the actions of company insiders, such as directors and officers, and their confidence in the company's performance.

Stakeholder Impact

• Shareholders may view the director's stock purchase as a positive sign, potentially increasing investor confidence.

Key Dates

Keywords

Form 4, CHEMED CORP, Director, Stock Acquisition, Beneficial Ownership, DeLyons Ron, Capital Stock